Multiple neuroendocrine carcinoma: a case report_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Hao ¹ , WU Chengyi ² ,  XU Jigang ¹ , CHEN Juan ³ , WANG Yalan ⁴

1. Department of Thoracic and Breast General Surgery, The People’s Hospital of Bishan Distrct, Chongqing 402760, P. R. China;
2. Department of Endocrinology and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China;
3. Department of Pathology, The People’s Hospital of Bishan Distrct, Chongqing 402760, P. R. China;
4. Department of Pathology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China;

Corresponding?author：

XU Jigang, Email: xujigangys@163.com

Keywords：

neuroendocrine carcinoma; multidisciplinary team; diagnosis; treatment

DOI：

10.7507/1007-9424.202002076

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the diagnosis and treatment of multiple neuroendocrine carcinoma.Method Clinical data of a case of multiple neuroendocrine carcinoma was retrospective analyzed.Results After discussion by a multidisciplinary team (MDT), the patient was diagnosed as multiple neuroendocrine carcinoma with late clinical stage and inoperable. Chemotherapy and radiotherapy were given, which showed significant effects, and the patient died after 1 year of follow-up.Conclusion In the clinical diagnosis and treatment of patients with multiple neuroendocrine carcinoma, MDT cooperative treatment model should be adopted to provide a better treatment program.

Citation： LIU Hao, WU Chengyi, XU Jigang, CHEN Juan, WANG Yalan. Multiple neuroendocrine carcinoma: a case report. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(8): 999-1004. doi: 10.7507/1007-9424.202002076 Copy

1.	Pearse AG. The diffuse neuroendocrine system and the apud concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol, 1977, 55(3): 115-125.
2.	Inzani F, Petrone G, Fadda G, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord, 2017, 18(4): 381-391.
3.	盛偉琪. 胃腸胰神經內分泌腫瘤病理診斷的規范和進展. 中國癌癥雜志, 2013, 23(6): 401-407.
4.	2013 年中國胃腸胰神經內分泌腫瘤病理診斷共識專家組. 中國胃腸胰神經內分泌腫瘤病理診斷共識 (2013 版). 中華病理學雜志, 2013, 42(10): 691-694.
5.	Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol, 2011, 2(1): 28-43.
6.	徐建明. 重視對胃腸胰腺神經內分泌腫瘤的認識. 中華腫瘤雜志, 2012, 34(2): 158-160.
7.	?berg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol, 2010, 21(Suppl 7): 72-80.
8.	中國臨床腫瘤學會神經內分泌腫瘤專家委員會. 中國胃腸胰神經內分泌腫瘤專家共識(2016年版). 臨床腫瘤學雜志, 2016, 21(10): 927-946.
9.	張太平, 李建, 趙玉沛. 胰腺神經內分泌腫瘤診治進展. 中華外科雜志, 2014, 52(9): 706-708.
10.	劉毫, 吳誠義, 呂忠柱. 胰腺神經內分泌腫瘤的綜合治療. 中國普外基礎與臨床雜志, 2016, 23(3): 369-373.
11.	岑超平, 陳曉, 李沖, 等. 胰腺神經內分泌腫瘤診治進展. 腫瘤基礎與臨床, 2015, 28(2): 178-179, 180.
12.	Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol, 2018, 31(12): 1770-1786.
13.	李潔, 孫宇, 吳佳懌. 胰腺和胃腸道來源神經內分泌腫瘤分類—2018 IARC/WHO分類框架共識解讀. 腫瘤綜合治療電子雜志, 2018, 4(4): 16-20.
14.	Scoazec JY, Couvelard A, Réseau TENpath. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol, 2017, 37(6): 444-456.
15.	郭鑫, 任思謙, 原春輝. 胰腺神經內分泌腫瘤綜合診治進展. 臨床外科雜志, 2019, 27(12): 1094-1098.
16.	Inzani F, Petrone G, Rindi G. The new World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am, 2018, 47(3): 463-470.
17.	王旭, 于鑫淼, 毛曉韻, 等. 乳腺神經內分泌癌的診斷及治療. 中國實用外科雜志, 2016, 36(7): 743-747.
18.	Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
19.	程悅, 黃子星, 宋彬. 胰腺神經內分泌腫瘤影像研究現狀及進展. 中國普外基礎與臨床雜志, 2020, 27(4): 489-493.
20.	Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991, 68(2): 227-232.
21.	Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
22.	Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC Study. Ann Oncol, 2013, 24(1): 152-160.
23.	Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
24.	Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol, 2007, 59(5): 637-642.
25.	Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer, 2011, 14(2): 161-165.

1. Pearse AG. The diffuse neuroendocrine system and the apud concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol, 1977, 55(3): 115-125.
2. Inzani F, Petrone G, Fadda G, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord, 2017, 18(4): 381-391.
3. 盛偉琪. 胃腸胰神經內分泌腫瘤病理診斷的規范和進展. 中國癌癥雜志, 2013, 23(6): 401-407.
4. 2013 年中國胃腸胰神經內分泌腫瘤病理診斷共識專家組. 中國胃腸胰神經內分泌腫瘤病理診斷共識 (2013 版). 中華病理學雜志, 2013, 42(10): 691-694.
5. Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol, 2011, 2(1): 28-43.
6. 徐建明. 重視對胃腸胰腺神經內分泌腫瘤的認識. 中華腫瘤雜志, 2012, 34(2): 158-160.
7. ?berg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol, 2010, 21(Suppl 7): 72-80.
8. 中國臨床腫瘤學會神經內分泌腫瘤專家委員會. 中國胃腸胰神經內分泌腫瘤專家共識(2016年版). 臨床腫瘤學雜志, 2016, 21(10): 927-946.
9. 張太平, 李建, 趙玉沛. 胰腺神經內分泌腫瘤診治進展. 中華外科雜志, 2014, 52(9): 706-708.
10. 劉毫, 吳誠義, 呂忠柱. 胰腺神經內分泌腫瘤的綜合治療. 中國普外基礎與臨床雜志, 2016, 23(3): 369-373.
11. 岑超平, 陳曉, 李沖, 等. 胰腺神經內分泌腫瘤診治進展. 腫瘤基礎與臨床, 2015, 28(2): 178-179, 180.
12. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol, 2018, 31(12): 1770-1786.
13. 李潔, 孫宇, 吳佳懌. 胰腺和胃腸道來源神經內分泌腫瘤分類—2018 IARC/WHO分類框架共識解讀. 腫瘤綜合治療電子雜志, 2018, 4(4): 16-20.
14. Scoazec JY, Couvelard A, Réseau TENpath. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol, 2017, 37(6): 444-456.
15. 郭鑫, 任思謙, 原春輝. 胰腺神經內分泌腫瘤綜合診治進展. 臨床外科雜志, 2019, 27(12): 1094-1098.
16. Inzani F, Petrone G, Rindi G. The new World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am, 2018, 47(3): 463-470.
17. 王旭, 于鑫淼, 毛曉韻, 等. 乳腺神經內分泌癌的診斷及治療. 中國實用外科雜志, 2016, 36(7): 743-747.
18. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
19. 程悅, 黃子星, 宋彬. 胰腺神經內分泌腫瘤影像研究現狀及進展. 中國普外基礎與臨床雜志, 2020, 27(4): 489-493.
20. Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991, 68(2): 227-232.
21. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
22. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC Study. Ann Oncol, 2013, 24(1): 152-160.
23. Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
24. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol, 2007, 59(5): 637-642.
25. Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer, 2011, 14(2): 161-165.

Previous Article
Right follicular thyroid carcinoma with metastases of cervical, mediastinum, axillary lymph nodes, and bilateral lungs: a case report

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Multiple neuroendocrine carcinoma: a case report

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content